Blazing Star Merger Sub completes Walgreens debt tender offer
Investing.com - BTIG has reiterated its Neutral rating on Hologic (NASDAQ:HOLX) following the company’s stronger-than-expected fiscal third quarter 2025 performance. According to InvestingPro data, the medical technology company currently trades slightly below its Fair Value, with 15 analysts recently revising their earnings expectations upward.
The medical technology company reported revenue of $1.024 billion, representing a 1.2% year-over-year increase (0.4% excluding foreign exchange effects, and -2.3% organic), which exceeded the top end of its guidance. The outperformance was driven by strength in the Skeletal Health and GYN-Surgical segments, while adjusted earnings per share came in 3 cents above Street expectations. InvestingPro analysis shows Hologic maintains strong financial health with a current ratio of 3.55 and operates with moderate debt levels.
Hologic’s management expressed confidence in its current position despite acknowledging ongoing challenges in its Breast Health segment, which may continue to see growth below mid-single digits in the first half of fiscal 2026. However, executives noted improving visibility on underlying business trends and a more favorable setup as comparisons ease.
BTIG highlighted that Hologic’s strong balance sheet will enable significant share repurchases, noting the company was buying back stock when shares were in the low-70s range. This aligns with InvestingPro data showing management’s aggressive share buyback strategy and the company’s robust cash position. Despite these positive factors, BTIG maintained its Neutral stance due to persistent challenges in the Breast Health segment and continuing headwinds in Diagnostics expected over the next few quarters. Subscribers can access 7 additional InvestingPro Tips and a comprehensive Pro Research Report for deeper insights into Hologic’s financial outlook.
For the fourth quarter of fiscal 2025, Hologic provided revenue and adjusted earnings guidance that exceeded Street expectations, reflecting what BTIG described as "incremental progress after a challenging" first half of fiscal 2025.
In other recent news, Hologic has reported its third-quarter 2025 earnings, surpassing Wall Street expectations. The company achieved an earnings per share of $1.08, exceeding the forecasted $1.05, and its revenue reached $1.024 billion, slightly above the anticipated $1.01 billion. Additionally, Hologic’s Skeletal Health segment posted $31 million in revenue, outperforming the expected $23 million, while the Interventional Breast segment delivered $100 million compared to Street expectations of $83 million. Following these strong quarterly results, Mizuho raised its price target for Hologic to $75.00 from $70.00, maintaining an Outperform rating. RBC Capital also upgraded Hologic’s stock from Sector Perform to Outperform, increasing its price target to $87.00 from $72.00. RBC anticipates Hologic will issue fiscal year 2026 organic revenue growth guidance that exceeds current estimates of 4.3%. These developments highlight significant investor interest and analyst optimism surrounding Hologic’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.